Welcome to our dedicated page for Soligenix SEC filings (Ticker: SNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Soligenix, Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical issuer developing rare-disease therapeutics and public health vaccine candidates. Form 8-K reports disclose clinical and regulatory events for HyBryte in cutaneous T-cell lymphoma and SGX945 (dusquetide) in Behçet's Disease, including trial-result announcements, orphan drug designations and corporate progress updates.
Registration statements and material-event filings describe Soligenix's capital structure, including common stock, warrants, preferred stock and at-the-market or public offering activity. The filing record also covers Nasdaq continued-listing compliance, material agreements, governance matters, operating and financial results, risk factors and shareholder voting matters tied to its drug-development pipeline.
Soligenix, Inc. reported an insider equity award to its chief scientific officer. On December 11, 2025, the officer received a stock option covering 100,000 shares of Soligenix common stock at an exercise price of $1.63 per share.
The option expires on December 10, 2035. According to the disclosure, 25% of the option vested immediately on December 11, 2025, and the remaining 75% will vest in 12 approximately equal installments on each three-month anniversary of that date.
Soligenix, Inc. reported an insider equity award to its Chief Financial Officer, Jonathan L. Guarino. He received a stock option grant covering 100,000 options to purchase common stock at an exercise price of $ 1.63 per share on December 11, 2025.
The option expires on December 10, 2035. It vested immediately as to 25% of the shares, with the remaining 75% scheduled to vest in 12 equal installments on each three month anniversary of December 11, 2025. Following this grant, he beneficially owns 100,000 derivative securities directly.
Soligenix, Inc. reported that its Chairman, CEO and President Christopher J. Schaber received a stock option grant covering 200,000 shares of common stock on December 11, 2025, with an exercise price of $1.63 per share and an expiration date of December 10, 2035. The option vests 25% immediately, with the remaining 75% vesting in 12 equal installments on each three-month anniversary of December 11, 2025.
Soligenix, Inc. reports that it has regained compliance with Nasdaq’s minimum stockholders’ equity listing standard. Nasdaq requires at least $2,500,000 of stockholders’ equity for companies on The Nasdaq Capital Market. In its Quarterly Report for the quarter ended September 30, 2025, Soligenix reported stockholders’ equity of $7,597,976, which exceeded this requirement. On November 18, 2025, Nasdaq sent a letter confirming the company is again in compliance and that the listing matter is closed.
Soligenix, Inc. filed Prospectus Supplement No. 2 to its March 21, 2025 prospectus, covering the offer and sale by the company of 408,640 shares of common stock underlying previously issued common warrants. The supplement incorporates the company’s Form 10‑Q for the quarter ended September 30, 2025.
In the 10‑Q, Soligenix reported cash and cash equivalents of $10,525,335 and stockholders’ equity of $7,597,976 as of September 30, 2025. The company recorded a net loss of $2,530,947 for Q3 2025 and $8,184,191 for the nine months ended September 30, 2025. The filing notes a completed September 29, 2025 public offering with total gross proceeds of approximately $7.5 million.
Soligenix also disclosed it received a Nasdaq notice on August 15, 2025 regarding minimum stockholders’ equity, and believes it has since regained compliance. Shares outstanding were 10,086,130 as of October 31, 2025.
Soligenix filed a prospectus supplement registering 4,253 shares of common stock underlying previously issued common warrants. The supplement incorporates the company’s Quarterly Report on Form 10‑Q for the period ended September 30, 2025.
Cash and cash equivalents were $10,525,335, and stockholders’ equity was $7,597,976 as of September 30, 2025. The company reported a net loss of $2,530,947 for the quarter. As of October 31, 2025, 10,086,130 shares were outstanding.
Soligenix noted it had received an August 2025 Nasdaq notice regarding the equity listing standard and believes it has regained compliance following a September 29, 2025 public offering with approximately $7.5 million in gross proceeds.
Soligenix (SNGX) filed Prospectus Supplement No. 2 to its March 21, 2025 prospectus, covering the resale of up to 1,054,688 shares of common stock issuable upon exercise of previously issued common warrants by selling stockholders. The supplement incorporates the company’s Form 10‑Q for the quarter ended September 30, 2025.
As of October 31, 2025, shares outstanding were 10,086,130. For Q3 2025, the company reported a net loss of $2,530,947, and for the nine months year‑to‑date a net loss of $8,184,191. Cash and cash equivalents were $10,525,335 as of September 30, 2025, and stockholders’ equity totaled $7,597,976.
Management noted it received a Nasdaq notice on August 15, 2025 for stockholders’ equity non‑compliance and believes it regained compliance following a September 29, 2025 public offering with total gross proceeds of approximately $7.5 million.
Soligenix filed its Q3 2025 10‑Q, reporting a smaller quarterly net loss and strengthened equity from recent financings. The company posted a net loss of $2,530,947 for the quarter and $8,184,191 year‑to‑date, with no 2025 revenue as it advances late‑stage programs. Research and development expense was $1,583,879 in the quarter and $5,202,573 year‑to‑date; general and administrative was $996,604 and $3,168,297, respectively.
Liquidity improved: cash and cash equivalents were $10,525,335, and stockholders’ equity rose to $7,597,976. The company completed a public offering on September 29, 2025 with total gross proceeds of approximately $7.5 million and executed ATM sales totaling $4,666,421 year‑to‑date. Convertible debt was fully repaid in February 2025.
Management states resources are sufficient for at least the next twelve months. Nasdaq notified the company in August about equity compliance; Soligenix believes it has regained compliance, supported by the September offering. The FLASH2 Phase 3 CTCL study is enrolling, with top‑line results anticipated in the second half of 2026.
Christopher J. Schaber, who serves as Chairman, CEO and President of Soligenix, Inc. (SNGX), reported an insider purchase on 10/02/2025. The filing shows he acquired 15,132 shares of the company’s common stock at a weighted-average price of $1.3217 per share; the report notes trades executed at prices ranging from $1.32 to $1.325. After the transaction, the filing reports he beneficially owned 15,511 shares (direct). The Form 4 was signed on 10/03/2025 and includes an undertaking to provide trade-level details on request.
Soligenix Schedule 13G summary: This filing reports that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC (the Reporting Persons) each may be deemed to beneficially own 446,408 shares of Soligenix common stock, representing 4.99% of the class as of the close of business on October 1, 2025. The filing explains ownership arises from warrants issued under a Securities Purchase Agreement dated September 25, 2025 and details earlier potential beneficial ownership figures tied to issuance and exercise of three warrants and a contemplated issuance of 425,000 shares to Intracoastal at closing. Blocker provisions in the warrants limit exercise to remain at or below specified ownership thresholds.